Elan Drug Technologies

25.01.10

Elan Drug Technologies Welcomes the NDA Approval of MS Drug AMPYRA(TM) (Dalfampridine) Extended Release Tablets

AMPYRA(TM) APPROVED USING ELAN'S PROPRIETARY MXDAS(TM) (MATRIX DRUG ABSORPTION SYSTEM) DRUG DELIVERY TECHNOLOGY

• » Read on

18.12.09

ELAN DRUG TECHNOLOGIES CELEBRATES 40 YEARS OF DRUG DELIVERY LEADERSHIP

DUBLIN, IRELAND, December 18th, 2009, Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) celebrates today its official anniversary and forty-years of leadership in the drug delivery business.   Since its founding in Ireland in 1969, Elan’s drug delivery ...

• » Read on

14.12.09

Elan Drug Technologies Announces First Japanese Approval of Product Using Its NanoCrystal® Technology.

DUBLIN, IRELAND, DECEMBER 14 2009, Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) announces the approval by the Japanese Ministry of Health, Labour and Welfare of EMEND® (aprepitant) for the treatment of cancer chemotherapy-induced nausea and vomiting.  ...

• » Read on

04.12.09

Elan Drug Technologies Announces Submission of MAA in Europe for Paliperidone Palmitate using NanoCrystal® tech

DUBLIN, IRELAND – December 4, 2009— Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) announced that Janssen-Cilag has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for paliperidone palmitate for the treatment of ...

• » Read on

03.08.09

Elan Drug Technologies announces first approval of a long acting injectable formulation using NanoCrystal® Technology

Fifth product approved by the US FDA licensing Elan’s NanoCrystal® technology for various

• » Read on

30.06.09

Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.

Acorda to Continue to Develop and Commercialize Fampridine-SR in the U.S. Upfront Payment

• » Read on

06.05.09

Acorda Therapeutics Announces FDA Acceptance of Fampridine-SR New Drug Application for Filing FDA Assigns Priority Review and PDUFA Date of October 22, 2009 No Current Therapies Indicated to Improve Walking Ability in People with MS

HAWTHORNE, N.Y.--(BUSINESS WIRE)--May. 6, 2009-- Acorda Therapeutics, Inc. (Nasdaq: ACOR)

• » Read on

23.04.09

Acorda Therapeutics Resubmits New Drug Application for Fampridine-SR for Improvement of Walking Ability in People with Multiple Sclerosis

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Apr. 23, 2009-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the resubmission of its New Drug Application (NDA) for Fampridine-SR to the U.S. Food and Drug Administration (FDA). Fampridine-SR is a novel therapy being developed to improve walking ...

• » Read on

02.02.09

Acorda Therapeutics Submits New Drug Application for Fampridine-SR for Improvement of Walking Ability in People with Multiple Sclerosis

•  Acorda Submitted New Drug Application (NDA) for Fampridine-SR on January 30, 2009  
• No Current Therapies Indicated to Improve Walking Ability in People with MS

HAWTHORNE, N.Y.--(BUSINESS ...

• » Read on

08.01.09

Victory Pharma announces launch of additional Naprelan® prescription products

SAN DIEGO (January 8, 2009) –Victory Pharma, Inc., a privately held specialty pharmaceutical company, today announced that it is launching two additional dosage strengths of NAPRELAN® (naproxen sodium) Controlled-Release Tablets. NAPRELAN is a once-daily, controlled-release ...

• » Read on

19.12.08

AstraZeneca and MAP Pharmaceuticals Announce Worldwide Collaboration to Develop and Commercialize Unit Dose Budesonide

LONDON and MOUNTAIN VIEW, Calif., Dec 19, 2008 /PRNewswire-FirstCall via COMTEX News Network AstraZeneca (NYSE: AZN) and MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today an exclusive worldwide agreement to develop and commercialize Unit Dose Budesonide (UDB), MAP ...

• » Read on

13.11.08

FDA Approves 30-Minute Onset of Action for Focalin® XR

Data indicate Focalin XR provides rapid and significant improvements in attention, behavior and academic productivity at 30 minutes post-dose EAST HANOVER, N.J., November 12, 2008 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved a 30-minute onset of action for ...

• » Read on

10.11.08

Azur Pharma and Elan Corporation Sign Agreement to Develop a Once-Daily Clozapine

DUBLIN, Ireland -- November 10, 2008 -- Azur Pharma Limited (“Azur”) today announced that it has entered into an agreement to develop and commercialise once-daily formulations of clozapine using Elan Corporation plc’s (“Elan”)(NYSE:ELN) proprietary drug delivery ...

• » Read on

08.07.08

Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day

Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day Tuesday July 8, 8:00 am ET Focalin XR demonstrated better symptom control versus Concerta from 30 minutes to six hours post-dose in ...

• » Read on

04.06.08

Acorda Therapeutics Announces Positive Data from Second Phase 3 Study of Fampridine-SR on Walking Ability in People with Multiple Sclerosis

Company Plans to File New Drug Application (NDA) in First Quarter of 2009 Investor Conference Call and Webcast Today at 8:30 A.M. ET HAWTHORNE, N.Y.--(BUSINESS WIRE)--June 2, 2008--Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced positive results from ...

• » Read on

27.11.07

Zogenix Licenses Exclusive U.S. Commercial Rights for Late Stage, Controlled-Release, Opioid Product from Elan

SAN DIEGO, CA (November 27, 2007)   Zogenix, Inc. (”Zogenix”), a private, specialty pharmaceutical company, today announced they have entered into a License Agreement under which Zogenix has been granted exclusive US rights from an affiliate of Elan Corporation, plc (NYSE: ...

• » Read on

29.10.07

Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate

Titusville, NJ (October 29, 2007) – Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for paliperidone palmitate, an investigational, once-monthly ...

• » Read on

05.09.06

Additional NanoCrystal® Technology Patent Issued

Spring Valley, NY, Sept. 5, 2006 – Par Pharmaceutical Companies, Inc. (NYSE:PRX) today announced that a new patent has been issued by the U.S. Patent and Trademark Office (PTO) relating to Megace®  ES (megestrol acetate) 625 mg/5 mL oral suspension, which utilizes Elan’s ...

• » Read on